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Genetic variation is an important source of pharmacokinetic variability and leads to 
modification of drug response. It is one of the several factors contributing to variability in 
drug disposition. Any alteration in drug disposition, influences circulating drug 
concentrations, as well as the concentrations at the sites of action. Drug disposition is mainly 
affected by drug metabolizing enzymes, drug transport proteins, plasma protein binding 
and transcription factors. The knowledge about the factors influencing drug disposition is 
useful in predicting potential drug interactions and pharmacokinetic variations. Among the 
above factors the most important mechanism by which genetic variation modifies drug 
response is by altering drug metabolizing enzymes that in turn alter drug metabolism. 
These enzymes are proteins that catalyse the chemical alteration of drugs and other 
molecules inside  the body. Metabolism converts most of the drug to inactive product but 
few others to more toxic product. The main organ for drug metabolism is liver; kidney, GI 
mucosa and lungs play smaller role. The drug metabolizing enzymes can either be 
functionalizing (oxidation, reduction, and hydrolysis) or conjugating (glutathione, 
glucuronide). Genetic variation in drug metabolizing enzymes can either increase or 
decrease drug metabolism. For example some individuals have genetically determined 
insufficiency to metabolise succinylcholine, a short-acting neuromuscular-blocking drug, 
widely used as muscle relaxant and in anaesthesia. It is normally rapidly hydrolysed by 
plasma cholinesterase. If succinylcholine is administered to such individual, he/she fails to 
inactivate succinylcholine rapidly and experiences prolonged neuromuscular block. This is 
because a recessive gene gives rise to an abnormal type of plasma cholinesterase and this 
abnormal enzyme has a modified pattern of substrate and inhibitor specificity. 
Plasma binding proteins often bind a large fraction of a drug in circulation Binding varies 
from drug to drug. Sometimes drug bind more than 99%. Albumin is main plasma protein 
to which drug bind and mostly acidic drug bind with plasma albumin. Other drug binding 
plasma proteins are globulin, alpha acid glycoprotein etc. Protein binding affects 
pharmacology of drug. It alters unbound drug concentration in circulation and only 
unbound (free) drug can enter tissues. So any genetic variation in plasma protein brings 
about variation in drug response. Similarly, transcription factors are proteins that regulate 
gene expression. When bound to exogenous chemicals, certain transcription factors induce 
the expression of drug metabolizing enzymes and modify drug response. Some genetically 
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determined drug response based on factor other than pharmacokinetic variation. Consider 
an example of the individuals having red blood cells deficient in an enzyme called glucose-
6- phosphate dehydrogenase. Deficiency of this enzyme increases the risk of hemolysis, if 
certain drugs such as aspirin and sulfonamides are administered.  
Differences in metabolism, transportation, plasma protein binding of drugs are significant 
factors affecting drug disposition and results modification of drug action. This chapter 
summarizes the reviews of the findings on genetic variation related with drug disposition. 
Genetic variation is an important source of pharmacokinetic as well as pharmacodynamic  
variability and leads to modification of drug response. It is one of several factors 
contributing to variability in drug disposition. The branch of science that deals with 
individual variation in drug response is termed pharmacogenetics. It deals with the genetic 
basis of variability of drug response in an individual and is a useful parameter for 
individualization of drug therapy. It is a rapidly emerging branch in which thousands of 
studies are carried out annually. Besides, it has important role in clinical practice and on 
drug development. 
Recently, pharmacogenetic deals with   the study of drug response in unrelated individuals. 
The difference in drug response is due to the variation of genotype, that encodes for drug-
metabolizing enzymes, receptors for the drug, drug transport proteins, transcription factors 
and various ion channels. A change in genotype or a mutation in gene sequence may 
increase  quantity  and/ or activity of a protein or an essential enzyme. In some cases, such a 
change results in an exaggerated or reduced therapeutic response to a drug. In general, 
variation in genotype account for15%–30% of inter-individual differences in drug 
metabolism and response, but for some drugs, genetic factors are of most common and 
account for up to 95% of inter-individual variability in drug disposition and effects. 
The important drugs under different therapeutic categories are shown in Table 1. 
The knowledge about the factor influencing drug disposition is useful in predicting 
potential drug interaction and pharmacokinetic variation.  
The genetic mechanisms for variation of drug response are variation in gene sequence. It 
includes changes in the primary nucleotide sequence of coding, regulatory, and splice 
regions of a gene. Less common forms are variability in the structure and function of the 
genome. Among these are sequence variation in microRNA (miRNA) binding sites, which 
affects the ability of miRNA to regulate translation; pharmacoepigenetics, which examines 
heritable chromatin modifications; and copy number variation.   
2. Pharmacokinetic variability 
The effectiveness of the medication is determined by how much of the drug is present at its 
site of action and how long sufficient concentrations of the drug remain at the site. 
Pharmacokinetics is the quantitative study of the time course of drug concentration in the 
body. It is the term used to describe the disposition of a drug throughout the body – that is, 
the drug’s absorption, distribution, metabolism, and excretion (ADME).  Pharmacokinetic 
variability is the variation in drug movement throughout the body. Drugs produce an effect  
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Sistonen J.Pharmacogenetic variation at CYP2D6, CYP2C9, AND CYP2C19. Population Genetic and 
Forensic Aspects Department of Forensic Medicine University of Helsinki Finland 2008 
Table 1. Common drug substrates of CYP2D6, CYP2C9, and CYP2C19 according to 
therapeutic Categories  
only if they can reach its physiological target(s) in sufficient concentration. These processes 
determine the fate of a drug in the body. A combination of metabolism and excretion 
constitutes drug elimination. Following factors are the sources of individual variation in 
drug disposition. 
1. Drug-metabolizing enzymes, 
2. Drug transport proteins,  
3. Receptors for the drug, 
4. Various ion channels 
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2.1 Drug-metabolizing enzymes 
Metabolism is biochemical reaction that takes place inside body. Almost all tissues are 
capable to metabolize drugs but the liver is the major site of metabolism. Besides liver, GI 
tract, kidney and lungs also metabolize certain fraction of drug. The main objective of 
metabolism is to convert lipophilic to hydrophilic so that drug is easily excreted from the 
body. In general, metabolites lack pharmacological activity and are more water soluble than 
the parent substance. But in few conditions, active metabolites are formed from inactive 
parent drugs; such parent drugs are termed as prodrug. The chemical reactions that involve 
in drug metabolism are categories into two types – Phase 1 reactions and – Phase 2 or 
conjugation reactions. 
Phase 1 reactions occur in the cytosol, mitochondria, microsomes of cells of the liver and 
other organs. It includes oxidation, reduction, hydrolysis, cyclization and decyclization 
reactions. Much phase I drug metabolism is performed by polymorphic enzymes, 
particularly various forms of cytochrome P450 (CYP). The influence of genetic 
polymorphisms of drugs metabolized by CYP2C9, CYP2C19, and CYP2D6 indicates 
polymorphisms and affects the metabolism of 20%–30% drugs.   
In Phase 2 reaction drugs or metabolites combine with other substances and results in 
increased water solubility of the substance, which decreases the amount that is reabsorbed 
through renal tubules and thereby increases the fraction that is excreted in the urine. It is 
also known as conjugation. The most common conjugation reaction is glucuronide, glycine, 
glutathione, glutamate and sulfate conjugation. 
The cytochrome P450s are a multigene family of enzymes found predominantly in the liver, 
that are responsible for metabolism. Genetically determined variability in the level of 
expression or function of these enzymes has a profound effect on drug efficacy. Genetic 
polymorphisms for many drug-metabolizing enzymes and drug targets have been 
identified. Polymorphisms refer to sequence variations with an allele frequency of greater 
than or equal to 1%. Polymorphism in any one of many genes—including those encoding 
drug receptors, drug transporter are important determinants of clinical response. 
Polymorphisms have now been identified in more than 20 human drug metabolizing 
enzymes. Important examples are polymorphisms in the cytochrome P450 enzymes and in 
thiopurine methyltransferase. Polymorphism not only affects drug disposition but can also 
be important in the conversion of prodrugs into their active form. For example, codeine is 
metabolized into the analgesic morphine by CYP2D6, and the desired analgesic effect is not 
achieved in CYP2D6 poor metabolizers.  
Cytochrome P450 system refers to a family of enzymes (usually hepatic) which are located 
on the endoplasmic reticulum, which performs oxidative metabolism of broad array of 
substances. Cytochrome P450 comprises the most important group of phase I enzymes. The 
most important CYP 450 enzymes are: 
CYP3A4 (50% of P450 metabolism) followed by 
CYP2D6 (20%),  
CYP2C9 and CYP2C19 (together 15%) 
Others: CYP2E1, CYP2A6, and CYP1A2. 
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2.1.1 Some common drug metabolizing enzymes and genetic polymorphisms 
CYP2D6— The notable substrates for this enzyme include the tricyclic antidepressants 
amitriptyline, clomipramine, desipramine, amphetamines, ß-blockers, imipramine, and 
nortriptyline. Metabolism of these drugs is influenced by the polymorphism in gene that 
code CYP2D6. Polymorphism in gene that code CYP2D6 may either  reduce the rate of the 
metabolism and increased plasma concentrations of above mentioned drugs when given in 
recommended doses, or it may enhance the rate of metabolism and results  into therapeutic 
failure because the drug concentrations at normal doses are far too low.  
CYP 3A4- The notable substrates for this enzyme include alprazolam, triazolam, 
carbamazepine, methadone, pimozide, quetiapine, risperidone, zolpidem. 
 
Daly AK. Pharmacogenetics and human genetic polymorphisms (2010). Biochem. J. 429: 435–449 
Table 2. CYP genes and polymorphic drug metabolism 
CYP2C9— The notable substrates for this enzyme include warfarin. tolbutamide, glipizide, 
and phenytoin. 
The CYP genes (See Table 2) have well characterized roles in pharmacogenetic studies on 
drug metabolism. Other CYP genes also contribute to drug and xenobiotic metabolism or 
have physiological roles, but pharmacogenetic data is more limited.  
2.2 Drug transport protein  
In addition to metabolizing enzymes, drug transport proteins also contribute to alteration in 
drug disposition. Many drugs are transferred by active transporter systems, membrane 
proteins that maintain both inward and outward transport of drugs and their metabolites in 
cells. Variation in a drug transporter producing a clinical impact is less common than is 
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observed for other pharmacokinetic mechanisms. However, there are examples of variation 
in drug transport that can be attributed to adverse drug effects. One such example is 
the SLCO1B1 gene that encodes a polypeptide, OATP1B1, which mediates hepatic uptake of 
anionic drugs, including most HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) 
inhibitors (statins). Although statins are the safest drugs, they sometimes develop myopathy 
in relatively small percentage of treated individuals. Variability in drug transporters also 
contributes to resistance to a variety of medicines, most commonly observed in the 
treatment of a variety of cancers. 
Transport proteins are embedded in a the cell membrane and responsible for transport of 
endogenous compounds or drugs into the cell or outside of the cell i.e. across the biological 
membranes. They are classified into either efflux or uptake proteins, depending on the 
direction of transport. The extent of expression of genes coding for transport proteins can 
have a profound effect on the bioavailability and pharmacokinetics of various drugs. 
Additionally, genetic variation such as single-nucleotide polymorphisms (SNPs) of the 
transport proteins can cause differences in the uptake or efflux of drugs. Genetic variants of 
transport proteins can cause or contribute to a number of diseases, such as anemia.  
There are two superfamilies of transport proteins that have important effects on the 
absorption, distribution, and excretion of drugs. These are the ATP-binding cassette (ABC) 
and the solute-carrier (SLC) superfamilies. 
ATP-binding cassette (ABC) transporters are present in cellular and intracellular membranes 
and can be responsible for either importing (influx) or removing (efflux) of substances from 
cells and tissues. They often transport substances against a concentration gradient by using 
the hydrolysis of ATP to drive the transport. 
2.2.1 ABC transporters 
There are at least 49 ABC transporter genes. These genes  are particularly important for drug 
transport. Genetic polymorphisms affecting ABC transporter genes expression or changing 
their affinity for substrates and alter the absorption and elimination of drugs. It also alters 
drug concentrations at the site of action despite similar blood concentrate. The majority of 
ABC transporters move compounds from the cytoplasm to the outside of a cell, although 
some of them move compounds into an intercellular compartment such as the endoplasmic 
reticulum, mitochondria, or peroxisome. ATP-binding transporters are responsible for the 
efflux of drugs and substrates, including bilirubin, several anticancer drugs, cardiac 
glycosides, immunosuppressive agents and glucocorticoids. 
2.2.2 Solute Carrier Proteins 
Solute carrier proteins (SLCs) are important in the transport of ions and organic substances 
across biological membranes in the maintenance of homeostasis. Members of the SLC 
superfamily consist of membrane channels, facilitative transporters, and secondary active 
transporters. Examples of some of the endogenous solutes that are transported include 
steroid hormones, thyroid hormones, and prostaglandins. Additionally, SLCs are important 
in the transport of a large number of drugs. In all, more than 40 families of transporters 
make up the SLC superfamily. Genetic variants of solute carrier proteins, such as SLC6A3 
gene encodes for the dopamine transporter DAT1, the SLC6A4 gene codes for the serotonin 
transporter (SERT) that has been associated with variation in drug response. 
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2.3 Receptors for the drug 
Receptors are the macromolecules that are located in cell membrane or inside cell  or in 
organism to which drugs bind to initiate the series of biochemical reaction that leads to 
biological response. Most receptors are regulatory proteins (hormones, neurotransmitter), 
enzymes (dihydrofolate reductase), transport proteins (Na+/K+ ATPase) and structural 
proteins (tubulin). Sequential variations in the receptor protein can affect target molecules or 
the structural integrity of the receptor and change ligand binding. 
Genetic variation not only varies towards drug response by altering metabolism but also 
have important role in drug receptors. A growing number of drug targets (e.g., receptors) 
are known to exhibit genetic polymorphisms and alter drug response in humans. Many 
researches have been conducted to show polymorphisms in the gene encoding 
receptor/effectors contribute variation in drug response e.g. ┚2-adrenergic receptor, is 
encoded by the gene ADRB2. This receptor interacts with endogenous catecholamines and 
various medications altering the effects of medications. Polymorphisms in the gene 
encoding this receptor have been associated with altered expression, down-regulation, and 
altered cell signaling and finally on clinical responses to endogenous and exogenous 
agonists. 
2.4 Various ion channels 
Ion channels are multimeric protein complexes and exert functionally overlapping control 
over excitability and signaling in both the plasma membrane and intracellular organelles. 
These channels control the electrical activity of muscles and nerves. There are various genes 
encoding the ion channels that have been identified.  
Ion channel genes constitute about 1.2% of known protein coding genes. Mutations of these 
genes alter the functioning of ion channel resulting into a diverse array of clinical disorders 
in the body, especially in brain, nerve, muscle and heart. Predisposition of some common 
disorders like migraine and epilepsy might be mediated by genetic variation in ion-channel 
genes. Genetic variation in cellular ion transporter can also have a role in the alteration of 
drug response. 
The most important ionic pores for generation and control of the action potential  are 
voltage-dependent sodium and potassium channels. Specific genes coding for these 
channels are expressed in the central nervous system. So, it could be expected that a 
mutation in these genes may be at the origin of unbalance between excitation and inhibition 
and thus could cause epilepsy. Three types of epilepsies have been linked to mutations in 
human genes encoding subunits of:  
 The neuronal nicotinic acetyl choline receptor (nAChR) (┙4, CHRNA4, and ┚2, 
CHRNB2, subunits),  
 The voltage-gated potassium (KCNQ2, KCNQ3) channels and  
 The voltage-gated sodium (SCN1A, SCN1B) channels.  
Mutations in CHRNA4 and CHRNB2 are associated with some cases of familial epilepsies 
classified as autosomal dominant nocturnal frontal lobe epilepsies with an important intra 
and interfamilial clinical heterogeneity. Mutations in voltage-gated potassium channels 
KCNQ2 and KCNQ3 have been identified in benign familial neonatal convulsions.  
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The sodium channel is composed of four homologous domains that contain well-characterized 
voltage-sensing and pore regions. The four domains form a sodium-permeable pore within the 
membrane that is remarkably selective for the individual ion that it conducts. Each domain 
comprises six membrane-spanning segments, each of which has an ┙-helical structure. And 
each sodium channel ┙ subunit associates with one or more different ┚ subunits. This 
association of ┙ and ┚ auxiliary subunits has an important influence on the voltage 
dependence, kinetics and cell-surface expression of most voltage-gated ion channels. Most 
neurological channelopathies associated with dysfunction of voltage-gated ion channels are 
caused by mutations in the gene encoding the pore-forming subunit. 
Myotonia is a clinical disorder in which patients experience muscle stiffness because of a 
failure of normal electrical inactivation of activated muscle. Myotonia can result from 
mutations in either the CLCN1 gene, that encodes the muscle voltage-gated chloride 
channel, or SCN4A encoding the voltage-gated sodium channel.  
3. Pharmacogenetics and adverse drug reactions 
Drug is any substance or product that is used or intended to be used to modify or explore 
the physiological system or pathological state for the benefit of the recipients. Interacting 
with receptors drugs not only produce desire effect but also produce undesired effect. Most 
undesirable effect associated with drugs is overdose/ poisoning, development of resistance, 
and adverse drug reaction (ADR). Amongst these effects ADR are important and leads to 
morbidity and mortality. Fortunately, when drugs are used properly, many ADR can be 
avoided or at least kept to a minimum. According to WHO 'ADR is any noxious, 
unintended and undesirable effect that occur at doses normally used in men for 
prophylaxis, diagnosis or therapy of the disease or modification of physiological function'. 
Adverse effect to drug may develop promptly or only after prolonged medication or even 
after stoppage of medications. Type B ADRs, which are not directly predictable from drug 
pharmacology and are unrelated to pharmacological actions of the drugs and often caused 
by immunological and pharmacogenetic mechanism, these effects are rare, but they are 
potentially very serious consequences for the patient. Type A (Predictable), can be 
predictable from drug pharmacology and is dose dependent. It is common and found to 
occur in 80%. It includes side effects, toxic effect, withdrawal symptoms.  
Polymorphisms in the genes that code for drug-metabolizing enzymes, drug transporters, drug 
receptors, and ion channels can alter drugs pharmacokinetics as well as pharmacodynamics. 
Polymorphism results in  individual’s risk of having adverse drug reactions 
Some pharmacogenetically determined adverse drug reactions include prolonged muscle 
relaxation after succinylcholine injection due to inherited deficiency of a plasma 
cholinesterase, resulting alteration of metabolism. Haemolysis is caused by antimalarials 
and sulfonamides due to glucose-6-phosphate dehydrogenase deficiency. 
It was found that the genetic polymorphism of the drug-metabolising enzyme CYP2D6 due 
to the antiarrhythmic drug, sparteine, is responsible for adverse drug reactions such as 
nausea, diplopia, and blurred vision. Similarly, orthostatic hypotension after the 
antihypertensive agent debrisoquine is also due to genetic polymorphism. It was found that 
ticlopidine induced hepatotoxicity. The incidence of hepatotoxicity is more common among 
Japanese patients than Europeans because hepatotoxicity is associated with HLA (human 
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leucocyte antigen) genes. HLA gene is predominantly presented in Japanese. 
Carbamazepine, a widely used anticonvulsant, can cause hypersensitivity  reactions but 
rarely  showed Stevens–Johnson syndrome. Various study showed that Taiwanese have 
high incidence of CBZ-induced Stevens–Johnson syndrome because they have very strong 
association between the HLA gene and CBZ-induced SJS. 
4. Clinical applications 
The importance of genetic variation has been best illustrated by the approval of BiDil, a 
cardiovascular combination product of isosorbide dinitrate and hydralazine, by FDA for the 
Afro-American population in 2005. Similar race- or gene-specific drugs are likely to be 
marketed in near future as a response to need for safer and more effective drugs. 
4.1 Cancer treatment 
Genetic variation at CYP2D6 has important therapeutic implications in cancer treatment. 
Tamoxifen are used to treat breast cancer. It is a pro-drug, requiring metabolic activation to 
active metabolites endoxifen and 4-hydroxytamoxifen. These reactions are catalyzed by 
CYP2D6. Variation in gene coding CYP2D6 enzyme activity has been shown to affect 
tamoxifen treatment outcomes. Besides, CYP2D6  polymorphism can also affect the efficacy 
of antiemetic drugs, which are often used for nausea and vomiting induced by cancer 
chemotherapy. Serotonin type receptor antagonist ondansetron, is metabolized by enzyme 
CYP2D6. CYP2D6-related rapid metabolism decrease therapeutic effect (severe emesis) and 
dose adjustment is necessary.  
4.2 Oral anticoagulation therapy 
Warfarin, as the most commonly used anticoagulation therapy, is indicated for the 
prophylaxis and/or treatment of thromboembolism. It is also indicated for treatment and 
prophylaxis of deep vein thrombosis, acute myocardial infarction, and stroke. Warfarine act 
as vitamin K antagonists by inhibiting the liver microsomal enzyme, vitamin K epoxide 
reductase, which is essential in the vitamin K cycle and formation of clotting factors. 
Warfarin is administered as a racemic mixture of R- and S-enantiomers, the latter of which is 
predominantly responsible for the anticoagulant effect and metabolized by CYP2C9. Similar 
doses of warfarin given to different individuals can result in varied drug responses. Patients 
with a two genetic variants have a significantly increased occurrence of a serious or life-
threatening bleeding incident. This is due genetic polymorphism of drug metabolizing 
enzyme CYP2C9. 
4.3 Proton Pump Inhibitor (PPI) therapy 
PPIs, such as omeprazole, lanzoprazole, are widely used for the treatment of acid-related 
diseases, including gastroesophageal reflux disease and peptic ulcer, as well as for the 
eradication of Helicobacter pylori in combination with antibiotics. PPIs are mainly 
metabolized by CYP2C19 in the liver, and the clinical outcome of drug therapy depends on 
genetic variation at the encoding gene CYP2C19. Ultra-rapid CYP2C19-related metabolism 
is an important factor contributing to therapeutic failures in drug treatment with PPIs, 
especially in European populations. 
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4.4 Psychiatric drug therapy 
Genetic variation is an important factor for the variation in psychiatric drug response. The 
meta-analysis conducted by Kirchheiner et al. showed that of 36 commonly used 
antidepressants, for 20 of those, data on polymorphic CYP2D6 or CYP2C19 were found and 
that in 14 drugs such genetic variation would require at least doubling of the dose in 
extensive metabolizers in comparison to poor metabolizers. They also showed that out of 38 
antipsychotics, CYP2D6 and CYP2C19 genotype was of relevant in 13 drugs. Amitriptyline  
has  relatively narrow therapeutic range  and high toxicity at increased concentrations, 
leading to severe adverse effects. The main CYPs involved in amitriptyline metabolism are 
CYP2C19. Genetic variation of these enzymes has been shown to correlate with the serum 
concentrations of amitriptyline, as well as with the occurrence of side-effects related to 
amitriptyline therapy. 
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